A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence

Inclusion Criteria: * Patients who have completed Study 339-14-001 * Patients who have signed the informed consent form for Study 339-14-002 Exclusion Criteria: * The patient has a clinically significant unstable illness (eg, complication of New York Heart Association (NYHA) class III or IV heart failure or angina pectoris, renal function disorder with estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1.73 m2, hepatic failure, and neoplastic disorder) * The patient has a clinically significant abnormal electrocardiogram (ECG) which is inappropriate for the participation in the trial in the opinion of the investigator or subinvestigator